BR112018076190A2 - ortólogos e sistemas crispr tipo vi - Google Patents

ortólogos e sistemas crispr tipo vi

Info

Publication number
BR112018076190A2
BR112018076190A2 BR112018076190A BR112018076190A BR112018076190A2 BR 112018076190 A2 BR112018076190 A2 BR 112018076190A2 BR 112018076190 A BR112018076190 A BR 112018076190A BR 112018076190 A BR112018076190 A BR 112018076190A BR 112018076190 A2 BR112018076190 A2 BR 112018076190A2
Authority
BR
Brazil
Prior art keywords
systems
orthologs
targeting
crispr type
rna
Prior art date
Application number
BR112018076190A
Other languages
English (en)
Inventor
S Lander Eric
Zhang Feng
Gootenberg Jonathan
O Abudayyeh Omar
Original Assignee
Massachusetts Inst Technology
Harvard College
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Harvard College, Broad Inst Inc filed Critical Massachusetts Inst Technology
Publication of BR112018076190A2 publication Critical patent/BR112018076190A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

a invenção fornece sistemas, métodos e composições para ácidos nucleicos de alvejamento. em particular, a invenção fornece sistemas de alvejamento de rna de ocorrência não natural ou geneticamente modificados que compreendem uma proteína efetora de crispr de alvejamento de rna inovadora e pelo menos um componente de ácido nucleico de alvejamento semelhante a um rna-guia.
BR112018076190A 2016-06-17 2017-06-19 ortólogos e sistemas crispr tipo vi BR112018076190A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662351803P 2016-06-17 2016-06-17
US201662351662P 2016-06-17 2016-06-17
US201662376377P 2016-08-17 2016-08-17
US201662410366P 2016-10-19 2016-10-19
US201662432240P 2016-12-09 2016-12-09
US201762471792P 2017-03-15 2017-03-15
US201762484786P 2017-04-12 2017-04-12
PCT/US2017/038154 WO2017219027A1 (en) 2016-06-17 2017-06-19 Type vi crispr orthologs and systems

Publications (1)

Publication Number Publication Date
BR112018076190A2 true BR112018076190A2 (pt) 2019-06-18

Family

ID=59295312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076190A BR112018076190A2 (pt) 2016-06-17 2017-06-19 ortólogos e sistemas crispr tipo vi

Country Status (9)

Country Link
US (3) US11788083B2 (pt)
EP (1) EP3455357A1 (pt)
JP (3) JP7267013B2 (pt)
KR (2) KR20190019168A (pt)
CN (1) CN109642231A (pt)
AU (4) AU2017283713B2 (pt)
BR (1) BR112018076190A2 (pt)
CA (1) CA3028158A1 (pt)
WO (1) WO2017219027A1 (pt)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11435358B2 (en) 2011-06-23 2022-09-06 Board Of Regents, The University Of Texas System Single molecule peptide sequencing
US9625469B2 (en) 2011-06-23 2017-04-18 Board Of Regents, The University Of Texas System Identifying peptides at the single molecule level
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
CA3208970A1 (en) 2014-09-15 2016-05-06 Board Of Regents, The University Of Texas System Improved single molecule peptide sequencing
CA2963820A1 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
JP7030522B2 (ja) 2015-05-11 2022-03-07 エディタス・メディシン、インコーポレイテッド 幹細胞における遺伝子編集のための最適化ｃｒｉｓｐｒ／ｃａｓ９システムおよび方法
CA2986262A1 (en) 2015-06-09 2016-12-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
US20190225955A1 (en) 2015-10-23 2019-07-25 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
WO2017091630A1 (en) 2015-11-23 2017-06-01 The Regents Of The University Of California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP3443086B1 (en) 2016-04-13 2021-11-24 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2569734B (en) 2016-09-30 2022-09-07 Univ California RNA-guided nucleic acid modifying enzymes and methods of use thereof
KR20230170126A (ko) 2016-09-30 2023-12-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Rna-가이드된 핵산 변형 효소 및 이의 사용 방법
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
JP7228514B2 (ja) * 2016-12-09 2023-02-24 ザ・ブロード・インスティテュート・インコーポレイテッド Ｃｒｉｓｐｒエフェクターシステムベースの診断法
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
US11739308B2 (en) * 2017-03-15 2023-08-29 The Broad Institute, Inc. Cas13b orthologues CRISPR enzymes and systems
US11021740B2 (en) 2017-03-15 2021-06-01 The Broad Institute, Inc. Devices for CRISPR effector system based diagnostics
US11104937B2 (en) 2017-03-15 2021-08-31 The Broad Institute, Inc. CRISPR effector system based diagnostics
US11174515B2 (en) 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
IL269458B2 (en) 2017-03-23 2024-02-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
BR112019021378A2 (pt) 2017-04-12 2020-05-05 Massachusetts Inst Technology ortólogos de crispr tipo vi inovadores e sistemas
US11618928B2 (en) 2017-04-12 2023-04-04 The Broad Institute, Inc. CRISPR effector system based diagnostics for malaria detection
US11591589B2 (en) 2017-04-21 2023-02-28 The General Hospital Corporation Variants of Cpf1 (Cas12a) with altered PAM specificity
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
CN110869498A (zh) 2017-05-10 2020-03-06 加利福尼亚大学董事会 经由核递送crispr/cas9导向编辑细胞rna
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP2020524497A (ja) 2017-06-09 2020-08-20 エディタス・メディシン，インコーポレイテッド 操作されたｃａｓ９ヌクレアーゼ
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2019005886A1 (en) * 2017-06-26 2019-01-03 The Broad Institute, Inc. CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
US11168322B2 (en) 2017-06-30 2021-11-09 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
AU2018346527A1 (en) * 2017-10-04 2020-05-07 Massachusetts Institute Of Technology Systems, methods, and compositions for targeted nucleic acid editing
US11633732B2 (en) 2017-10-04 2023-04-25 The Broad Institute, Inc. CRISPR effector system based diagnostics
EP3697906A1 (en) 2017-10-16 2020-08-26 The Broad Institute, Inc. Uses of adenosine base editors
EP3701042A4 (en) * 2017-10-23 2021-08-11 The Broad Institute, Inc. SYSTEMS, PROCEDURES AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING
BR112020008654A2 (pt) 2017-11-01 2020-11-10 The Regents Of The University Of California composições casz e métodos de uso
WO2019089808A1 (en) 2017-11-01 2019-05-09 The Regents Of The University Of California Class 2 crispr/cas compositions and methods of use
US11332736B2 (en) 2017-12-07 2022-05-17 The Broad Institute, Inc. Methods and compositions for multiplexing single cell and single nuclei sequencing
US20210071163A1 (en) * 2017-12-22 2021-03-11 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted rna base editing
CA3086550A1 (en) * 2017-12-22 2019-06-27 The Broad Institute, Inc. Crispr effector system based multiplex diagnostics
FI3746568T3 (fi) * 2018-01-29 2023-12-12 Broad Inst Inc Crispr-efektorijärjestelmään perustuva diagnostiikka
CN108559738A (zh) * 2018-02-12 2018-09-21 南昌大学 一种植物rna修饰和编辑的***及方法
AU2019236210A1 (en) 2018-03-14 2020-09-10 Arbor Biotechnologies, Inc. Novel CRISPR DNA targeting enzymes and systems
FI3765616T3 (fi) 2018-03-14 2023-08-29 Arbor Biotechnologies Inc Uusia CRISPR-DNA- ja RNA-kohdennusentsyymejä ja -järjestelmiä
US20210189386A1 (en) * 2018-03-30 2021-06-24 POiRT Systems Co., Ltd. Nucleic acid construct, medicinal composition, anticancer agent, antiviral agent and antibacterial agent
CN108796036B (zh) * 2018-04-03 2021-11-19 交弘生物科技(上海)有限公司 基于原核Argonaute蛋白的核酸检测方法及其应用
JP7399876B2 (ja) * 2018-04-16 2023-12-18 ジョージア テック リサーチ コーポレーション 病態治療のためのＲＮＡエディターのｍＲＮＡ駆動型発現
EP3781670A4 (en) * 2018-04-20 2021-11-10 The Regents of the University of California FUSION PROTEINS AND RIBONUCLEIC ACIDS FOR TRACKING AND MANIPULATION OF CELLULAR RNA
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US20210198664A1 (en) 2018-05-16 2021-07-01 Arbor Biotechnologies, Inc. Novel crispr-associated systems and components
CN108546718B (zh) * 2018-05-16 2021-07-09 康春生 crRNA介导的CRISPR/Cas13a基因编辑***在肿瘤细胞中的应用
CN110527697B (zh) * 2018-05-23 2023-07-07 中国科学院分子植物科学卓越创新中心 基于CRISPR-Cas13a的RNA定点编辑技术
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement
WO2020006036A1 (en) 2018-06-26 2020-01-02 Massachusetts Institute Of Technology Crispr effector system based amplification methods, systems, and diagnostics
WO2020006067A1 (en) 2018-06-26 2020-01-02 The Broad Institute, Inc. Crispr double nickase based amplification compositions, systems, and methods
WO2020000454A1 (zh) * 2018-06-29 2020-01-02 深圳市博奥康生物科技有限公司 一种表达LwCas13a基因的质粒、构建方法及其应用
EP3827093A4 (en) * 2018-07-23 2022-10-05 Board of Regents, The University of Texas System IDENTIFICATION BY SINGLE MOLECULE SEQUENCING OF POST-TRANSLATIONAL MODIFICATIONS ON PROTEINS
WO2020022461A1 (ja) * 2018-07-25 2020-01-30 国立研究開発法人産業技術総合研究所 植物における標的ｄｎａのメチル化を抑制する方法
KR20210053898A (ko) * 2018-07-31 2021-05-12 더 브로드 인스티튜트, 인코퍼레이티드 신규 crispr 효소 및 시스템
EP3830301B1 (en) 2018-08-01 2024-05-22 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
AU2019336793A1 (en) * 2018-09-06 2021-04-08 The Regents Of The University Of California RNA and DNA base editing via engineered ADAR recruitment
EP3650553B1 (en) * 2018-11-07 2023-07-12 Siemens Healthcare GmbH Method for detection of specific nucleic acids
EP3880844A2 (en) 2018-11-14 2021-09-22 President And Fellows Of Harvard College Multiplexing highly evolving viral variants with sherlock detection method
MX2021005701A (es) 2018-11-14 2021-09-23 Broad Inst Inc Sistema crispr a base de sistemas y métodos de diagnóstico de gotas.
EP3882345A4 (en) * 2018-11-15 2023-02-22 China Agricultural University CRISPR-CAS12J ENZYME AND SYSTEM
US20220282275A1 (en) * 2018-11-15 2022-09-08 The Broad Institute, Inc. G-to-t base editors and uses thereof
WO2020124050A1 (en) 2018-12-13 2020-06-18 The Broad Institute, Inc. Tiled assays using crispr-cas based detection
WO2020142754A2 (en) 2019-01-04 2020-07-09 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20220154258A1 (en) 2019-03-14 2022-05-19 The Broad Institute, Inc. Crispr effector system based multiplex diagnostics
US20220177863A1 (en) 2019-03-18 2022-06-09 The Broad Institute, Inc. Type vii crispr proteins and systems
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
CA3134400A1 (en) * 2019-03-26 2020-10-01 Peking University Method for identifying functional elements
CN109913502A (zh) * 2019-04-16 2019-06-21 和元生物技术（上海）股份有限公司 一种Cas9-gRNA表达***及其应用
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
US20220403356A1 (en) * 2019-07-12 2022-12-22 Duke University 3' utr crispr-dcas 13 engineering system and methods of using same
CN110819652A (zh) * 2019-08-21 2020-02-21 山东金城生物药业有限公司 一种谷氨酸棒杆菌同时基因敲除及基因表达抑制的双功能***及应用
KR20220097875A (ko) 2019-09-03 2022-07-08 마이얼로이드 테라퓨틱스, 인크. 게놈 통합을 위한 방법 및 조성물
US20220333208A1 (en) 2019-09-03 2022-10-20 The Broad Institute, Inc. Crispr effector system based multiplex cancer diagnostics
CN115175996A (zh) * 2019-09-20 2022-10-11 博德研究所 新颖vi型crispr酶和***
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
AU2020395113A1 (en) 2019-12-02 2022-06-09 Shape Therapeutics Inc. Therapeutic editing
US20230078498A1 (en) * 2020-02-07 2023-03-16 University Of Rochester Targeted Translation of RNA with CRISPR-Cas13 to Enhance Protein Synthesis
CN111337666B (zh) * 2020-02-12 2021-04-02 山东大学 I-motif重组介导的FRET探针及其原位成像癌细胞表面蛋白质同源二聚化的应用
CN115315519A (zh) * 2020-02-28 2022-11-08 辉大(上海)生物科技有限公司 VI-E型和VI-F型CRISPR-Cas***及其用途
US11453907B2 (en) 2020-03-23 2022-09-27 The Broad Institute, Inc. Crispr effector system based coronavirus diagnostics
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
JP7419168B2 (ja) * 2020-06-10 2024-01-22 株式会社東芝 改変型ｐｉｇｇｙＢａｃトランスポゼースのポリペプチド、それをコードするポリヌクレオチド、導入キャリア、キット、細胞のゲノムに目的配列を組込む方法及び細胞製造方法
CN116096875B (zh) * 2020-09-30 2023-12-01 辉大(上海)生物科技有限公司 工程化的CRISPR/Cas13***及其用途
WO2022188039A1 (en) 2021-03-09 2022-09-15 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
WO2022068912A1 (en) 2020-09-30 2022-04-07 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
CN112430586B (zh) * 2020-11-16 2021-09-07 珠海舒桐医疗科技有限公司 一种VI-B型CRISPR/Cas13基因编辑***及其应用
WO2022136370A1 (en) * 2020-12-22 2022-06-30 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Application of crispr/cas13 for therapy of rna virus and/or bacterium induced diseases
EP4276182A1 (en) * 2021-01-05 2023-11-15 Kawasaki Gakuen Educational Foundation Transcriptional product in cells of organism including human, transfected rna, and tool for purifying complex thereof
BR112023024985A2 (pt) 2021-06-01 2024-02-20 Arbor Biotechnologies Inc Sistemas de edição de genes compreendendo uma crispr nuclease e usos dos mesmos
WO2023282710A1 (ko) * 2021-07-08 2023-01-12 한국과학기술원 Cas13 단백질의 활성 조절을 통한 rna 발현 조절 또는 편집 방법
EP4373963A2 (en) 2021-07-21 2024-05-29 Montana State University Nucleic acid detection using type iii crispr complex
EP4215612A1 (en) * 2022-01-20 2023-07-26 Sartorius Stedim Cellca GmbH Genome editing with crispr/cas nucleases comprising collateral activity

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
GB9114259D0 (en) 1991-07-02 1991-08-21 Ici Plc Plant derived enzyme and dna sequences
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
JP2952041B2 (ja) 1992-07-27 1999-09-20 パイオニア ハイ−ブレッド インターナショナル，インコーポレイテッド 培養ダイズ細胞のａｇｒｏｂａｃｔｅｒｉｕｍ媒介形質転換の改良法
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
CA2163129A1 (en) 1993-05-17 1994-11-24 Flossie Wong-Staal Ribozyme gene therapy for hiv infection and aids
US5789156A (en) 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
WO1996039154A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
NZ520579A (en) 1997-10-24 2004-08-27 Invitrogen Corp Recombinational cloning using nucleic acids having recombination sites and methods for synthesizing double stranded nucleic acids
US6750059B1 (en) 1998-07-16 2004-06-15 Whatman, Inc. Archiving of vectors
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7868149B2 (en) 1999-07-20 2011-01-11 Monsanto Technology Llc Plant genome sequence and uses thereof
US6603061B1 (en) 1999-07-29 2003-08-05 Monsanto Company Agrobacterium-mediated plant transformation method
GB0024550D0 (pt) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
AU2002336760A1 (en) 2001-09-26 2003-06-10 Mayo Foundation For Medical Education And Research Mutable vaccines
GB0125216D0 (en) 2001-10-19 2001-12-12 Univ Strathclyde Dendrimers for use in targeted delivery
US20090100536A1 (en) 2001-12-04 2009-04-16 Monsanto Company Transgenic plants with enhanced agronomic traits
AU2002353231B2 (en) 2001-12-21 2008-10-16 Oxford Biomedica (Uk) Limited Method for producing a transgenic organism using a lentiviral expression vector such as EIAV
ATE485031T1 (de) 2002-06-28 2010-11-15 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
EP1558724A4 (en) 2002-11-01 2006-08-02 New England Biolabs Inc ORGANIC RNA SCREENING AND ITS USE IN INTERRUPTING GENE TRANSMISSION IN THE ENVIRONMENT
ES2559828T3 (es) 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
NZ581166A (en) 2003-09-15 2011-06-30 Protiva Biotherapeutics Inc Polyethyleneglycol-modified lipid compounds and uses thereof
GB0325379D0 (en) 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
ATE536418T1 (de) 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc Lipidverkapselte interferenz-rna
JP4764426B2 (ja) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
JP4772045B2 (ja) 2004-07-16 2011-09-14 アメリカ合衆国 Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
GB0422877D0 (en) 2004-10-14 2004-11-17 Univ Glasgow Bioactive polymers
US7838658B2 (en) 2005-10-20 2010-11-23 Ian Maclachlan siRNA silencing of filovirus gene expression
EP1950294B1 (en) 2005-10-28 2012-01-18 Mitsubishi Tanabe Pharma Corporation Novel cell penetrating peptide
CA2628300C (en) 2005-11-02 2018-04-17 Protiva Biotherapeutics, Inc. Modified sirna molecules and uses thereof
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
JP2008078613A (ja) 2006-08-24 2008-04-03 Rohm Co Ltd 窒化物半導体の製造方法及び窒化物半導体素子
US20100099858A1 (en) 2006-09-28 2010-04-22 Mirkin Chad A Maximizing Oligonucleotide Loading on Gold Nanoparticle
CA2670096A1 (en) 2006-11-21 2008-05-29 The Samuel Roberts Noble Foundation, Inc. Biofuel production methods and compositions
WO2008149176A1 (en) 2007-06-06 2008-12-11 Cellectis Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof
CN101970051A (zh) 2007-12-31 2011-02-09 纳诺科尔治疗公司 用于治疗心力衰竭的rna干扰
DK2279254T3 (en) 2008-04-15 2017-09-18 Protiva Biotherapeutics Inc PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
EP2283029A1 (en) 2008-06-04 2011-02-16 Medical Research Council Peptides
US8999945B2 (en) 2008-06-30 2015-04-07 Silenseed Ltd Methods, compositions and systems for local delivery of drugs
US20110117189A1 (en) 2008-07-08 2011-05-19 S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. Ophthalmic compositions for treating pathologies of the posterior segment of the eye
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
GB2465749B (en) 2008-11-25 2013-05-08 Algentech Sas Plant cell transformation method
WO2010096488A1 (en) 2009-02-17 2010-08-26 The Regents Of The University Of California Method of reducing acetylation in plants to improve biofuel production
US8236943B2 (en) 2009-07-01 2012-08-07 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein B
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US20110027239A1 (en) 2009-07-29 2011-02-03 Tissue Genesis, Inc. Adipose-derived stromal cells (asc) as delivery tool for treatment of cancer
US8927807B2 (en) 2009-09-03 2015-01-06 The Regents Of The University Of California Nitrate-responsive promoter
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
US20120003201A1 (en) 2010-04-21 2012-01-05 Nicholas Susanne B Vault agents for chronic kidney disease
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
US8372951B2 (en) 2010-05-14 2013-02-12 National Tsing Hua University Cell penetrating peptides for intracellular delivery
WO2011148194A1 (en) 2010-05-28 2011-12-01 Oxford Biomedica (Uk) Ltd Delivery of lentiviral vectors to the brain
WO2012027675A2 (en) 2010-08-26 2012-03-01 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US20120295960A1 (en) 2011-05-20 2012-11-22 Oxford Biomedica (Uk) Ltd. Treatment regimen for parkinson's disease
EP2751567B1 (en) 2011-09-01 2019-05-08 University of Iowa Research Foundation Oligonucleotide-based probes for detection of bacterial nucleases
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
US20130185823A1 (en) 2012-01-16 2013-07-18 Academia Sinica Mesoporous silica nanoparticle-mediated delivery of dna into arabidopsis root
UA118014C2 (uk) * 2012-05-25 2018-11-12 Те Ріджентс Оф Те Юніверсіті Оф Каліфорнія Спосіб модифікації днк-мішені
CN105188767A (zh) 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
US8614194B1 (en) 2012-07-25 2013-12-24 Kaohsiung Medical University Anionic cell penetrating peptide and its use for intracellular delivery
CN110669746B (zh) 2012-10-23 2024-04-16 基因工具股份有限公司 用于切割靶dna的组合物及其用途
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
EP3434776A1 (en) 2012-12-12 2019-01-30 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
RU2721275C2 (ru) 2012-12-12 2020-05-18 Те Брод Инститьют, Инк. Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
SG10201912327SA (en) 2012-12-12 2020-02-27 Broad Inst Inc Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
CA2894668A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells
DK2921557T3 (en) 2012-12-12 2016-11-07 Broad Inst Inc Design of systems, methods and optimized sequence manipulation guide compositions
PL2921557T3 (pl) 2012-12-12 2017-03-31 Broad Inst Inc Projektowanie systemów, sposoby i optymalizowane kompozycje kierujące do manipulacji sekwencją
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
JP6625971B2 (ja) 2013-06-17 2019-12-25 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のためのタンデムガイド系、方法および組成物の送達、エンジニアリングおよび最適化
EP3011035B1 (en) 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
AU2014281030B2 (en) 2013-06-17 2020-07-09 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
EP3011033B1 (en) 2013-06-17 2020-02-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
WO2014204729A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
CN113425857A (zh) 2013-06-17 2021-09-24 布罗德研究所有限公司 用于肝靶向和治疗的crispr-cas***、载体和组合物的递送与用途
AU2014281027A1 (en) 2013-06-17 2016-01-28 Massachusetts Institute Of Technology Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
KR20160089526A (ko) 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 입자 전달 성분을 이용한 표적 장애 및 질병에 대한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 이용 및 치료 적용
CA3012631A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CA3024543A1 (en) * 2015-10-22 2017-04-27 The Broad Institute, Inc. Type vi-b crispr enzymes and systems
US11118194B2 (en) * 2015-12-18 2021-09-14 The Regents Of The University Of California Modified site-directed modifying polypeptides and methods of use thereof
CA3004491A1 (en) * 2016-01-08 2017-07-13 The Regents Of The University Of California Conditionally active heterodimeric polypeptides and methods of use thereof
US11427837B2 (en) * 2016-01-12 2022-08-30 The Regents Of The University Of California Compositions and methods for enhanced genome editing
WO2017136335A1 (en) * 2016-02-01 2017-08-10 The Regents Of The University Of California Self-inactivating endonuclease-encoding nucleic acids and methods of using the same
CA3048963A1 (en) * 2016-02-11 2017-08-17 The Regents Of The University Of California Methods and compositions for modifying a mutant dystrophin gene in a cell's genome
WO2017160752A1 (en) * 2016-03-14 2017-09-21 Intellia Therapeutics, Inc. Methods and compositions for gene editing
EP3436077A1 (en) * 2016-03-30 2019-02-06 Intellia Therapeutics, Inc. Lipid nanoparticle formulations for crispr/cas components
US20190093128A1 (en) * 2016-03-31 2019-03-28 The Regents Of The University Of California Methods for genome editing in zygotes
WO2017189336A1 (en) * 2016-04-25 2017-11-02 The Regents Of The University Of California Methods and compositions for genomic editing
US10337051B2 (en) * 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
JP7228514B2 (ja) * 2016-12-09 2023-02-24 ザ・ブロード・インスティテュート・インコーポレイテッド Ｃｒｉｓｐｒエフェクターシステムベースの診断法
US11174515B2 (en) * 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
US11021740B2 (en) * 2017-03-15 2021-06-01 The Broad Institute, Inc. Devices for CRISPR effector system based diagnostics

Also Published As

Publication number Publication date
AU2021203747A1 (en) 2021-07-01
JP2023134453A (ja) 2023-09-27
AU2017283713B2 (en) 2021-04-08
EP3455357A1 (en) 2019-03-20
US11788083B2 (en) 2023-10-17
CA3028158A1 (en) 2017-12-21
AU2018271372A1 (en) 2019-01-17
AU2017283713A1 (en) 2018-12-20
KR20190019168A (ko) 2019-02-26
US20240191223A1 (en) 2024-06-13
WO2017219027A1 (en) 2017-12-21
US20190359971A1 (en) 2019-11-28
KR20230156150A (ko) 2023-11-13
JP2023052051A (ja) 2023-04-11
JP2019524072A (ja) 2019-09-05
AU2021203747B2 (en) 2023-11-09
CN109642231A (zh) 2019-04-16
JP7267013B2 (ja) 2023-05-01
AU2023204078A1 (en) 2023-07-13
US20230383282A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
BR112018076190A2 (pt) ortólogos e sistemas crispr tipo vi
AU2018251801A8 (en) Novel type VI CRISPR orthologs and systems
MX2020011939A (es) Nuevas enzimas y sistemas crispr.
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
AU2018320870A1 (en) RNA targeting methods and compositions
EP3645054A4 (en) COMPOSITIONS BASED ON CRISPR / CAS-ADENIN-DEAMINASE, SYSTEMS AND METHODS FOR TARGETED NUCLEIC ACID EDITING
WO2016205749A8 (en) Novel crispr enzymes and systems
WO2017127807A8 (en) Crystal structure of crispr cpf1
EP3692145A4 (en) NUCLEIC ACID TARGETED EDITING SYSTEMS, METHODS AND COMPOSITIONS
EP3684397A4 (en) SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED EDITION OF NUCLEIC ACIDS
WO2017184786A8 (en) Cpf1 complexes with reduced indel activity
EP3701025A4 (en) SYSTEMS, PROCEDURES AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING
MX2020006072A (es) Métodos y composiciones relacionados con cpf1 para la edición genica.
EA201892489A1 (ru) Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
EP3701042A4 (en) SYSTEMS, PROCEDURES AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING
WO2016154127A3 (en) Compositions and methods for treating hypertriglyceridemia
BR112018010805A2 (pt) mutantes de proteína f de rsv
EA201991555A1 (ru) Композиции и способы усиления или увеличения продукции ifn i типа
AU2017306676A8 (en) Adenosine nucleobase editors and uses thereof
BR112019000195A2 (pt) composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno
WO2018109170A3 (en) Il-11ra antibodies
WO2015023975A8 (en) Compositions and methods for modulating rna
BR112018010341A2 (pt) composição, sistema e método para tratamento do cabelo, método para alteração da cor do cabelo, e, kit de multicompartimentos para alteração da cor ou do formato do cabelo.
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
BR112018010381A2 (pt) composições para tratamento de cabelo, condicionadora de cabelo e para alteração da cor do cabelo, sistema para tratamento de cabelo, métodos para tratamento de cabelo e para alteração da cor do cabelo, e, kit de multicompartimentos.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]